Bushwhacked by Alex Berenson on Fox News

Professional jealousy is an ugly thing

Jan 15, 2022

Alex Berenson goes on Fox News and directly calls me a liar to my face and says I didn’t invent RNA vaccines.

Unprofessional, rude and an arsehole to boot.

But beyond that, I think we can all assume CONTROLLED OPPOSITION.

So, for Alex, who evidently doesn’t know how to do an internet search, find a patent and read it - I will make it easy for him.

First - a couple of proof of principle experiments conducted in 1989 -from the patents with the priority date of 1989 (issued later, but the ideas/experiments date to March 21, 1989 as decided by the United States Patent Office)

Early Patents priority dates from 1989

The first patents:

Lipid-mediated polynucleotide administration to deliver a biologically active peptide and to induce a cellular immune response (includes mRNA). P Felgner, JA Wolff, GH Rhodes, R Malone, D Carson. Assigned to Vical, Inc and licensed to Merck. No. 7,250,404, date of issue: 7/31/07 Cited in 105 articles. Priority Date: 3/21/1989.
Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc and licensed to Merck. US Pat. Ser. No. 6,867,195 B1. Date of issue: 3/15/05. Priority Date: 3/21/1989.
Generation of an immune response to a pathogen (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc and licensed to Merck. US Pat. Ser. No. 6,710,035. Date of issue: 3/23/04. Citations: 39 articles. Priority Date: 3/21/1989.
Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 6,673,776. Date of issue: 1/6/04. Priority Date: 3/21/1989.
Methods of delivering a physiologically active polypeptide to a mammal (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 6,413,942. Date of issue: 7/2/02. (cited in 150 articles). Priority Date: 3/21/1989.
Induction of a protective immune response in a mammal by injecting a DNA sequence (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, licensed to Merck. US Pat. Ser. No. 6,214,804, date of issue: 4/10/01. Cited in 360 articles. Priority Date: 3/21/1989.
Induction of a protective immune response in a mammal by injecting a DNA sequence (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 5,589,466. Date of issue: 12/31/96. Cited in 899 articles. Priority Date: 3/21/1989.
Delivery of exogenous DNA sequences in a mammal (includes mRNA). Assigned to Vical, Inc, licensed to Merck. P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. US Pat. Ser. No. 5,580,859. Date of issue: 12/3/96. Cited in 1244 articles. Priority Date: 3/21/1989.
Generation of antibodies through lipid mediated DNA delivery (includes mRNA). P Felgner, JA Wolff, GH Rhodes, Robert W Malone, D Carson. Assigned to Vical, Inc, licensed to Merck. US Pat. Ser. No. 5,703,055. Date of issue: 12/30/97. Cited in 419 articles. Priority Date: 3/21/1989.
Below are some of the descriptions of the invention taken from the above patents - priority date 1989.

Some of my papers and other patents on this subject area (1988-2000)

A novel approach to study packaging of retroviral RNA by RNA transfection (Abstract). RW Malone, P. Felgner, I. Verma. RNA Tumor Viruses, May 17-18, 1988. Cold Spring Harbor (the first in a series of papers/abstracts on RNA transfection).
mRNA Transfection of cultured eukaryotic cells and embryos using cationic liposomes. Malone RW. Focus. 1989; 11:61-8
The SALK patent that was filed with the USPTO on 3/21/1989. Note that the cover letter hides this - and says it was filed on 3/29/89 - the sane date as all the VICAL patents, showing that there was collusion. WRITTEN BT ME IN 1988.
THE VERY FIRST mRNA VACCINE EXPERIMENTAL DATA 1990 (from Vical to patent office)
Cationic liposome-mediated RNA transfection. Malone RW, Felgner PL, Verma IM. Proc Natl Acad Sci (PNAS) U S A. 1989;86(16):6077-81. Cited in 749 articles.
Direct gene transfer into mouse muscle in vivo. Wolff JA, Malone RW, et al. Science. 1990;247(4949 Pt 1):1465-8. Cited in 4,750 articles. Note that Robert was a student at Northwestern, and was never affiliated with University of Wisc.
High levels of messenger RNA expression following cationic liposome mediated transfection tissue cultured cells. Malone R, Kumar R, Felgner P. NIH Conference: “Self-Cleaving RNA as an Anti-HIV Agent (abstract). Washington, DC June 1989.
Cationic liposome-mediated RNA transfection. Dwarki VJ, Malone RW, Verma IM. Methods Enzymol. 1993;217:644-54. Cited in: 102 articles.
Delivery of exogenous DNA (includes mRNA) sequences in a mammal P Felgner, JA Wolff, GH Rhodes, R Malone, D Carson. Biotechnology Advances 1993: 15 (3-4), 763-763

For a deeper dive into the actual data, patent disclosures, meeting notes, lab books, etc, go to this webpage.

Patents and papers - from the 1990s

DNA vaccines for eliciting a mucosal immune response (includes mRNA). US Pat. Ser. No. 6,110,898. Inventors: RW Malone and Jill Glasspool Malone. Date of issue: 8/29/00. Cited in 40 articles. Priority Date: 1996.
Formulations and methods for generating active cytofectin: polynucleotide transfection complexes. Robert W Malone, et al. US Pat. Ser. No. 5,925,623 7/20/99.
Cationic Transport Reagents. US Pat. Ser. No. 5,892,071 Robert W Malone, et. al. issued 4/06/99.
Polyfunctional cationic cytofectins, formulations and methods for generating active cytofectin: polynucleotide transfection complexes. Robert W Malone, et. al. US Pat. Ser. No. 5,824,812 issued 10/20/98.
Cationic Transport Reagents. Robert W Malone, et. al. US Pat. Ser. No. 5,744,625 issued 4/28/98.
Cationic Transport Reagents. Robert W Malone, et. al. US Pat. Ser. No. 5,527,928, date of issue: 6/18/96.
Marked enhancement of macaque respiratory tissue transfection by aurintricarboxylic acid. Glasspool-Malone J, …, Malone RW. Gene Med. 2002;4(3):323-2.
Enhancing direct in vivo transfection with nuclease inhibitors and pulsed electrical fields. Glasspool-Malone J, Malone RW. In Gene Therapy Methods: Methods Enzymol. 2002;346:72-91
Cutaneous transfection and immune responses to intradermal nucleic acid vaccination are significantly enhanced by in vivo electropermeabilization. Drabick JJ, Glasspool-Malone J, …, Malone RW. Mol Ther. 2001;3(2):249-55. Cited in 192 articles.
Theory and in vivo application of electroporative gene delivery. Somiari S, Glasspool-Malone J, … Malone RW. Mol Ther. 2000;2(3):178-87. Cited in 345 articles.
Efficient nonviral cutaneous transfection. Glasspool-Malone J, …, Malone RW. Mol Ther. 2000;2(2):140-6. Cited in 138 articles.
Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy. Berlyn KA, …, Malone RW J Biotechnol. 1999;73(2-3):155-79
Models of Cationic Liposome Mediated Transfection. Gene Therapy and Molecular Biology. Ahearn A, Malone RW. Vol 4. Gene Therapy and Molecular Biology 1999;4
Cationic lipid-mediated gene delivery to murine lung: correlation of lipid hydration with in vivo transfection activity. Bennett MJ, …, Malone RW, Nantz MH. J Med Chem. 1997;40(25):4069-78
Considerations for the design of improved cationic amphiphile-based transfection reagents. Bennett MJ, …, Malone RW. Journal of Liposome Research 1996;6(3):545-65
Structural and functional analysis of cationic transfection lipids: the hydrophobic domain. Balasubramaniam RP, …, Malone RW. Gene Ther. 1996;3(2):163-72. cited in 172 articles.
A flexible approach to synthetic lipid ammonium salts for polynucleotide transfection. MJ Bennett, RW Malone, MH Nantz. Tetrahedron letters 36 (13), 2207-2210

For the written history of the early events, by Dr. Jill Glasspool Malone

Fox was not to blame for this in any way. The producer apologized to me after. One can heard the moderator in the background saying that guests shouldn't attack guests. Fox was blind-sided too. This was not even the topic to be discussed - which was censorship -and the pressure on Spotify to now censor their podcasts, including censorship of Joe Rogan. That is 270 people in the science, medicine, healthcare write a letter complaining and then main stream media calls for Spotify to censor their podcasts.

This is a conversation that needs to happen now. As Spotify is now having Rolling Stone calling for them to censor for "public health reasons" If Spotify goes down that garden path, we all lose another alternative news source. That would be huge.

If Spotify censors because 270 doctors write a letter, but ignores the 16,000 that have signed the declaration - it would be a new low in the censorship battle. The move towards hard authoritarianism that this country and many countries in the world are moving towards is real. That is authoritarianism to maintain fascist (really Oligarch) control of big tech, pharma and social media. This is not about public health policy. To remind people, the censorship includes covering up a lab leak that kills millions of people (intensional or not?). They are covering up about why the USA has one of the highest death rates in the world, why the USG has stopped/suppressed early treatment, why the USG refuses to study the adverse events or allow reporting on the adverse events, why Fauci/Collins are allowed to conduct smear campaigns by using big media (such as against the authors of the Great Barrington Declaration), etc. The list goes on and on.

Instead of that discussion, I had Berenson attacking my credentials and early treatment.

Yeh, that seems like controlled opposition to me.

The question did someone who paid him to do that?

Expand full comment

54 replies